Cormedix (HAM:19KA) Cyclically Adjusted FCF per Share: €-0.91 (As of Mar. 2026)


HAM:19KA Cormedix Inc HAM:19KA
46 GF Score
Price €7.59
GF Value €59.38
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Cormedix Cyclically Adjusted FCF per Share?

Cormedix HAM:19KA -1.28% 46 Cyclically Adjusted FCF per Share is €-0.91 as of Mar. 2026. GuruFocus rates HAM:19KA with a GF Score™ of 46/100 and a GF Value™ of €59.38 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Cormedix's adjusted free cash flow per share for the three months ended in Mar. 2026 was €0.387. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.91 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 11.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 6.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Cormedix was 20.70% per year. The lowest was 1.00% per year. And the median was 5.30% per year.

As of today (2026-07-13), Cormedix's current stock price is €7.586. Cormedix's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-0.91. Cormedix's Cyclically Adjusted Price-to-FCF of today is .


Cormedix  (HAM:19KA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Cormedix Cyclically Adjusted FCF per Share Related Terms


Cormedix Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Cormedix's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cormedix Cyclically Adjusted FCF per Share Chart

Cormedix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -1.11

Cormedix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -1.11 -0.91

HAM:19KA vs STTK, ACHV, EIKN: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Cormedix's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cormedix Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cormedix's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Cormedix's Cyclically Adjusted Price-to-FCF falls into.


HAM:19KA
46GF Score
Cormedix Inc HAM:19KA
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cormedix Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cormedix's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.387/330.2130*330.2130
=0.387

Current CPI (Mar. 2026) = 330.2130.

Cormedix Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.460 241.018 -0.630
201609 -0.747 241.428 -1.022
201612 -0.762 241.432 -1.042
201703 -0.778 243.801 -1.054
201706 -0.656 244.955 -0.884
201709 -0.475 246.819 -0.635
201712 -0.468 246.524 -0.627
201803 -0.382 249.554 -0.505
201806 -0.225 251.989 -0.295
201809 -0.233 252.439 -0.305
201812 -0.302 251.233 -0.397
201903 -0.283 254.202 -0.368
201906 0.006 256.143 0.008
201909 -0.150 256.759 -0.193
201912 -0.136 256.974 -0.175
202003 -0.277 258.115 -0.354
202006 -0.026 257.797 -0.033
202009 -0.210 260.280 -0.266
202012 -0.152 260.474 -0.193
202103 -0.155 264.877 -0.193
202106 -0.068 271.696 -0.083
202109 -0.140 274.310 -0.169
202112 -0.151 278.802 -0.179
202203 -0.160 287.504 -0.184
202206 -0.130 296.311 -0.145
202209 -0.149 296.808 -0.166
202212 -0.142 296.797 -0.158
202303 -0.220 301.836 -0.241
202306 -0.175 305.109 -0.189
202309 -0.144 307.789 -0.154
202312 -0.176 306.746 -0.189
202403 -0.278 312.332 -0.294
202406 -0.227 314.175 -0.239
202409 -0.209 315.301 -0.219
202412 -0.087 315.605 -0.091
202503 0.265 319.799 0.274
202506 0.361 322.561 0.370
202509 0.300 324.800 0.305
202512 0.841 324.054 0.857
202603 0.387 330.213 0.387

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.91 mean?
Cormedix (HAM:19KA) has a Cyclically Adjusted FCF per Share of €-0.91 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Cormedix and its competitors.
Is Cormedix's Cyclically Adjusted FCF per Share too high?
Cormedix's current Cyclically Adjusted FCF per Share is €-0.91. Overall, Cormedix has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cormedix's Cyclically Adjusted FCF per Share compare to STTK and ACHV?
Cormedix's Cyclically Adjusted FCF per Share of €-0.91 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Cormedix and its competitors. Cormedix's current Cyclically Adjusted FCF per Share is €-0.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cormedix stock overvalued right now?
Based on GuruFocus' analysis, Cormedix (HAM:19KA) is currently considered Possible Value Trap. The stock's GF Value™ is €59.38, compared to a current price of €7.59 — trading 87.2% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.91. Cormedix's overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Cormedix (HAM:19KA), the current Cyclically Adjusted FCF per Share is €-0.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cormedix (HAM:19KA) Overvalued in 2026?

Based on GuruFocus' analysis, Cormedix stock appears to be undervalued. The current stock price of €7.59 is trading 87.2% below its estimated GF Value™ of €59.38. GuruFocus considers Cormedix to be Possible Value Trap.

Key valuation signals for HAM:19KA:

  • Cyclically Adjusted FCF per Share: €-0.91
  • GF Value™: €59.38 vs. price of €7.59 (87.2% below fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the HAM:19KA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cormedix Business Description

Other Exchanges CRMD:USA19KA:Germany
Address 389 Interpace Parkway, Suite 450, Parsippany, NJ, USA, 07054
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
46GF Score

Get the complete analysis for HAM:19KA

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.59
Price
€59.38
GF Value